← Markets

IQVIA Holdings Inc.

IQV · NYSE

Market closed$206.26$-4.23 (-2.01%)After hours $208.96 · +1.31%

Key statistics

Previous close$210.49
Open$207.59
Day high$211.62
Day low$205.80
52-week high$247.05
52-week low$154.50
Market cap34.42B
Volume1.09M
Average volume1.64M
P/E ratio17.00
Forward P/E—
EPS12.13
Dividend yield0.00%

Market context

Why it moved

IQV rose today driven by positive investor sentiment following an IQVIA executive's congressional testimony on modernizing U.S. clinical trial regulations, combined with an analyst price target upgrade from Argus citing AI-driven drug discovery tailwinds and the stock being identified as trading below its fair value.

FacebookMarketbeatBriefingFacebookMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026IQVIA Holdings closed down about 2% amid a broad healthcare sector pullback and tech-driven risk-off sentiment, though shares are recovering modestly in after-hours trading. On the same day, IQVIA's Dr. Cynthia Verst testified before a congressional subcommittee advocating for a more efficient path from drug discovery to first-in-human trials in the U.S., reinforcing the company's policy influence and clinical development positioning. Broader market headwinds — including a deteriorating AI narrative, U.S.-Iran tensions, and weakness in the healthcare sector ETF (XLV) — weighed on the stock despite IQVIA's strong Q1 2026 results and a recently raised full-year EPS outlook.

-2.0096

July 17, 2026IQVIA Holdings closed higher, outperforming the broader healthcare sector (XLV) as the company drew investor attention following congressional testimony by a senior IQVIA executive advocating for a more efficient path from scientific discovery to first-in-human drug trials — a signal of the company's growing regulatory influence. This came against a broadly positive backdrop for the healthcare sector, where UnitedHealth Group's strong Q2 earnings beat and raised guidance lifted sentiment across life sciences, and UBS upgraded the sector citing improving earnings revisions and accelerating AI adoption in drug discovery and clinical development. IQVIA's own Q1 2026 results, which saw record revenue, double-digit R&D bookings growth, and a record backlog of $34.2 billion, continued to underpin investor confidence heading into Q2 earnings season.

1.7794

July 16, 2026IQVIA Holdings edged slightly lower in regular trading but is rebounding in after-hours, gaining over 1.7%, after a wave of analyst price target upgrades boosted sentiment. Mizuho raised its target to $230 from $215, Baird lifted its target to $252 from $249, and Leerink Partners increased its target to $240 from $213 — all maintaining Outperform ratings — reflecting growing confidence in IQVIA's outlook ahead of Q2 earnings season. The broader healthcare sector saw mixed action, with UBS upgrading its sector view and noting that AI adoption in drug discovery and clinical development is driving a new earnings improvement cycle for life science tools companies.

-0.4908

July 15, 2026IQVIA Holdings closed essentially flat as multiple analysts raised their price targets following a strong Q1 2026 earnings beat. Mizuho lifted its target to $230 from $215 and Baird increased its target to $252 from $249, both maintaining Outperform ratings, contributing to a consensus average target of ~$230 — implying roughly 11% upside. The stock held steady despite broader healthcare sector headwinds, with XLV under pressure from Abbott's decline and a softer earnings outlook, while a cooler-than-expected June CPI report provided a modest tailwind for equities overall.

0.1349

July 14, 2026IQVIA Holdings closed essentially flat amid a broader market pullback driven by renewed U.S.-Iran tensions and surging oil prices, with Mizuho raising its price target to $230 from $215 while maintaining an Outperform rating. Investor sentiment is also being shaped by Artisan Partners' newly disclosed stake in IQVIA, citing the company's AI-driven data analytics platform — including its IQVIA.ai partnership with NVIDIA — and recurring-revenue model as key differentiators in a competitive CRO landscape.

-0.1443

July 11, 2026IQVIA Holdings edged down modestly, underperforming the broader healthcare sector (XLV) as investors weigh a confluence of bullish catalysts ahead of the company's Q2 2026 earnings on July 28. Deutsche Bank initiated a 'Catalyst call: Buy' on July 9, RBC Capital maintained its Buy with a $221 target, and Evercore ISI raised its price target to $225 from $195 — all signaling growing institutional conviction. Artisan Partners' newly disclosed position further validated the bull case, citing AI resilience and attractive valuation at ~15x forward earnings despite lingering concerns over CRO demand softness.

-0.536

July 10, 2026IQVIA Holdings gained over 2.5% on July 9, outperforming the broader healthcare sector (XLV) and the S&P 500, as a wave of bullish analyst activity converged with renewed institutional interest. Deutsche Bank initiated a 'Catalyst call: Buy' on the stock, Artisan Partners disclosed a new position citing AI resilience and upside, and earlier in the week both Evercore ISI and Argus raised their price targets to $225 and $235, respectively. With Q2 earnings scheduled for July 28 and the stock still trading below most analyst consensus targets near $229, investors appear to be positioning ahead of the print — particularly after prior weakness driven by CRO demand concerns and AI disruption fears created what value-oriented funds like Artisan viewed as an attractive entry point.

2.5418

July 9, 2026IQVIA Holdings closed down ~2% as a broader market risk-off selloff — triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging over 5% and stoking inflation fears — weighed on the stock. This came despite a constructive analyst backdrop, with Argus, Evercore ISI, HSBC, and Baird all raising price targets on IQV in recent days (consensus target ~$230), and ahead of the company's scheduled Q2 2026 earnings call on July 28. Lingering sector concerns around AI disruption and CRO demand softness persist, though value-oriented investors like Artisan Mid Cap Value Fund have recently initiated positions, citing low valuations at ~15x forward earnings.

-2.1323

Stock Titan · July 16, 2026IQVIA Seeks Faster Path From Discovery to Human Drug TrialsSimply Wall Street · July 16, 2026Is IQVIA Holdings (IQV) Undervalued As Earnings Growth Anchors A $227 Fair Value?MarketScale · July 16, 2026IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpointsMoomoo · July 9, 2026RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $221Quiver Quantitative · June 24, 2026IQVIA Gains as Investors Reassess Strong Backlog, Raised EPS Outlook | IQV Stock NewsInvesting.com · June 17, 2026Morgan Stanley downgrades IQVIA stock rating on margin concernsBusiness Wire · June 3, 2026IQVIA Announces Offering of Senior NotesQuiver Quantitative · May 28, 2026IQVIA jumps 9.3% as investors refocus on raised 2026 profit outlook and buyback support
Mt Newswire · July 13, 2026Mizuho Adjusts Price Target on IQVIA Holdings to $230 From $215, Maintains Outperform Rating
Benzinga · July 13, 2026Mizuho Maintains Outperform on IQVIA Holdings, Raises Price Target to $230
Mt Newswire · July 7, 2026Argus Adjusts Price Target on IQVIA Holdings to $235 From $215
Mt Newswire · July 6, 2026HSBC Adjusts Price Target on IQVIA Holdings Inc to $240 From $210
Benzinga · July 1, 2026Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $249
Mt Newswire · June 18, 2026Rothschild & Co Redburn Adjusts IQVIA Price Target to $284 From $287, Maintains Buy Rating
Mt Newswire · June 17, 2026IQVIA Shares Fall After Morgan Stanley Downgrade
Benzinga · June 17, 2026Morgan Stanley Downgrades IQVIA Holdings to Equal-Weight, Lowers Price Target to $200

Peers

S&P 500SPX · $7,457.78-1.01%ICON Public Limited CompanyICLR · $170.000.00%Charles River Laboratories International, Inc.CRL · $224.35-2.10%Medpace Holdings, Inc.MEDP · $537.73-0.04%Labcorp Holdings Inc.LH · $283.36+0.50%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%Agilent Technologies, Inc.A · $131.46-3.41%Waters CorporationWAT · $368.98-2.44%Bio-Techne CorporationTECH · $72.12+0.49%Fortrea Holdings Inc.FTRE · $17.76-0.89%West Pharmaceutical Services, Inc.WST · $358.48-1.09%Mettler-Toledo International Inc.MTD · $1,310.02-1.88%